BioXcel Therapeutics (FRA:BX2) 3-Year EBITDA Growth Rate : -14.50% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics 3-Year EBITDA Growth Rate?

BioXcel Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was €-0.58.

During the past 3 years, the average EBITDA Per Share Growth Rate was -14.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -34.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioXcel Therapeutics was -14.50% per year. The lowest was -146.10% per year. And the median was -43.50% per year.

Competitive Comparison of BioXcel Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, BioXcel Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioXcel Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's 3-Year EBITDA Growth Rate falls into.

BioXcel Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

BioXcel Therapeutics (FRA:BX2) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BioXcel Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

BTAI:USA BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines